Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... According to a new Aegis Living Study on ... likely to worry about what will happen to their memory ... 69% Silent Generation), which may help explain why nearly half ... particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). The ... among more than 2,000 U.S. adults ages 18+. , ...
(Date:5/22/2015)... 2015 The dentist in ... that they are now offering complimentary consultations to ... treatments. At consultations, patients can discuss their candidacy ... certain treatments can achieve and whether alternative options ... initial appointment. If treatments are chosen, patients can ...
(Date:5/22/2015)... 22, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing , is proud ... respected All American National athlete, to the Wimbledon Athletics ... the high level of testing and information it provides ... their athletic trainers, this way they can focus on ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened for ... they have concentrated their focus to working with over ... of this growth and their goals to better serve ... Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, Texas. ... offices, dental start ups, orthodontic practices, pediatric dental practices, ...
(Date:5/22/2015)... 22, 2015 In efforts to offer ... section containing particular muscles stretches has been a large ... of stretches now complete, Chunk Fitness envisions a mid-June ... be filmed and released at a later point in ... here: http://www.chunkfitness.com/stretches . , About the Company: Chunk ...
Breaking Medicine News(10 mins):Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3
... paramedics shortens time to specialized treatment, study finds , ... people with chest pain who are given an electrocardiogram ... long to receive treatment to open their arteries. , ... and go directly to the cardiac catheterization laboratory for ...
... ... Flying Aid and Orange Israel Telecommunications have announced today that they are aiding ... children. This will be the first of three stages of establishing the orphanage ... IDF - will be providing fresh, running drinking water, an electric generator, tents ...
... less likely to opt for surgery than county hospitals, ... The type of treatment received by prostate cancer patients ... where they receive care, a new U.S. study has ... in county hospitals, while patients in private facilities ...
... , WASHINGTON , Jan. 25 ... disability advocates, The HSC Foundation is currently accepting applications for its ... the ages of 14 and 26 in the Washington, DC ... , Applicants will be evaluated on their current and previous work ...
... , ... OrthoAccel Technologies, Inc., developers of the AcceleDent System , ... week that it has engaged Waldemar "Val" B. Szwajkowski ... the Company will be primarily focused on strategic development of ...
... ... 5W Public Relations ( http://www.5wpr.com ) , one of the 25 ... of Philip Stein ( http://www.philipstein.com/ ) watches to its versatile roster ... quickly grown to be a leader in watches and other lifestyle products using ...
Cached Medicine News:Health News:Israel Flying Aid, Orange Israel Create Haiti Orphanage, Provide Humanitarian Aid 2Health News:Israel Flying Aid, Orange Israel Create Haiti Orphanage, Provide Humanitarian Aid 3Health News:Israel Flying Aid, Orange Israel Create Haiti Orphanage, Provide Humanitarian Aid 4Health News:Prostate Cancer Care Varies By Hospital Type 2Health News:DC Nonprofit Searches for Next Generation of Disability Advocates 2Health News:Industry Advisor Joins OrthoAccel Technologies, Inc. 2Health News:Industry Advisor Joins OrthoAccel Technologies, Inc. 3Health News:Industry Advisor Joins OrthoAccel Technologies, Inc. 4Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3
(Date:5/22/2015)... 22, 2015 According to a ... Product (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, ... Cytometry), by End Users - Global Forecast to 2020", ... expected to reach $736.85 Million by 2020 from $452.36 ... Browse 71 market data Tables and ...
(Date:5/22/2015)... BOSTON , May 22, 2015   InspireMD, Inc. ... in stent embolic protection systems ("EPS"), today announced that its ... PARADIGM, lead by principle investigator Prof. Piotr Musialek , ... in Paris, France . PARADIGM, ... pe R cutaneous c A roti D revascularization ...
(Date:5/22/2015)... R.I. , May 22, 2015 ... once-daily central nervous system stimulant indicated for the ... to patients beginning Summer 2015. ... XR received approval from the U.S. Food and ... is an extended-release formulation of methylphenidate capsule with ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: